ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Hyperion Therapeutics, Inc." (HPTX) Report Updated: Nov 24, 2014 | Print This Page

Get more stock ratings by Louis Navellier

"Hyperion Therapeutics, Inc." (HPTX)

Rating: Sell Volatility: Aggressive
Total Grade: D Industry: Biotechnology
Competitors: ENTA, AGIO, MACK, MDXG

Stock Analysis

Rating: Monthly View

A
B
C
D
F
November December January February March April May June July August September October

Rating: Weekly View

This Week: D down no change
Last Week: D same downgrade
Two Weeks Ago: C up no change
service keys

"Hyperion Therapeutics, Inc."© quotemedia

Company Profile

Hyperion Therapeutics, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology. It is developing Ravicti, which has completed two Phase II trials and one Phase III trial for the treatment of adult and pediatric urea cycle disorders patients; and is in Phase II clinical trial for the treatment of hepatic encephalopathy. The company was founded in 2006 and is headquartered in South San Francisco, California.

Recent News: "Hyperion Therapeutics, Inc."